Answers are grounded in this paper and cite their sources.
Serological testing of large representative populations for antibodies to SARS-CoV-2 is needed to estimate seroprevalence, transmission dynamics, and the duration of antibody responses from natural infection and vaccination. In this study, a high-throughput SARS-CoV-2 multiplex microsphere immunoassay (MMIA) was developed for the receptor binding domain (RBD) and nucleocapsid (N) that was more sensitive than enzyme-linked immunosorbent assay (ELISA) (98% versus 87%).
No takes yet. Share an insight, caveat, or question.
Schultz et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: